Business
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactio
About this update from Lb Pharmaceuticals Inc
[{"type":"image","alt":"LB Pharmaceuticals Inc","displaySize":"","headline":null,"caption":"LB Pharmaceuticals Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.x_fLVJc153Yix9eSgj33w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2","width":300,"height":136}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel.","length":340,"tagName":"p"},{"type":"text","content":"Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance.","length":177,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Minako to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer. “Dr. Pazdera has broad expertise encompassing both financial and strategic transactions, as well a deep understanding of intellectual property law and corporate compliance. Her contributions will be invaluable as we advance the development of LB-102 and work towards our broader vision of building a fully integrated CNS-focused company.”","length":444,"tagName":"p"},{"type":"text","content":"Before joining LB Pharmaceuticals, Dr. Pazdera served as General Counsel and Corporate Secretary at Kardigan. Previously, she was General Counsel and Corporate Secretary at Carmot Therapeutics where she led the legal function during its dual track IPO/strategic transaction process, resulting in the acquisition of Carmot by Roche for up to $3.1 billion in 2024. Her earlier roles encompassed both strategic and intellectual property functions at Lyell Immunopharma, Sangamo Therapeutics and Genentech, as well as in private practice. Dr. Pazdera holds a J.D. from the Fordham University School of Law, a Ph.D. in Biological Sciences from Carnegie Mellon University, and a B.A. in Molecular and Cell Biolo...